Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
Hepatocellular carcinoma (HCC) is the most common type of liver
cancer and the prevalence and mortality rate of liver cancer has
been rising steadily over the past decade. Liver cancer is still on
the rise and death rates are increasing faster than any other type
of cancer. Fortunately for patients with HCC, new agents have become
available in the past few years, including novel immunotherapies.
They have shown the ability to improve safety and efficacy outcomes,
especially with dual immune checkpoint blockade in the 1st-line
advanced HCC setting. Several immunotherapies are currently
undergoing late stage clinical trials or regulatory review as well
in advanced HCC. For the treatment of HCC, transplantation is an
option for patients. Unfortunately, there is a limited supply of
good-quality deceased donor organs. Thus, other treatments,
including systemic therapy, should be used to bridge patients to
transplant or to delay recurrence if possible, in HCC. Fortunately,
clinicians have been equipped with new individualized options in the
past few years, including immunotherapies, which provide options for
the unmet need of treatment in HCC, especially in dual immune
checkpoint blockade in the 1st-line advanced HCC setting. Several
PD-L1 immunotherapy options are currently undergoing late stage
clinical trials or regulatory review that have shown the ability to
continue to close gaps in treatment for patients with advanced HCC.
Immune checkpoint inhibitors have shown improved efficacy and safety
in HCC, and healthcare professionals must be educated on these
options, how they should be integrated into the treatment paradigm,
and the potential risks that come along with any treatment option.
Upon completion of this
activity, participants will be able to:
Examine the biologic rationale for
integrating immunotherapy into the treatment armamentarium for
Analyze recent clinical trial data
surrounding new and emerging immunotherapies, including dual
immunotherapy combinations, in HCC for informed decision-making
Identify patients with advanced HCC
for whom immunotherapies, including dual immune checkpoint
blockade, is an appropriate choice for the next step in the
management of their cancer, especially in the 1st-line advanced
Compare and contrast the mechanisms
of action, safety and efficacy of new and emerging
immunotherapies, and their combinations, in the treatment of HCC
Discuss strategies for anticipating,
recognizing, and managing adverse events of immunotherapies in
Assess the managed care
considerations of dual immune checkpoint blockade combinations
by exploring where these agents fit into current advanced HCC
||Richard S. Finn, MD
Professor of Medicine
Geffen School of Medicine, Division of
University of California Los Angeles
serves as a consultant for AstraZeneca, Bayer,
Bristol-Myers Squibb, Eisai, Eli Lilly, Cstone,
Roche/Genentech, Merck, and Pfizer. He has received
grant/research support from Eisai, Eli Lilly, Merck,
Pfizer, and Roche/Genentech. His presentation has been
peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue